precision peptide FAQ

Reduce the dose by 50% immediately and increase hydration and electrolyte intake. VIP's vasodilatory effect is dose-dependent and reversible within hours. If systolic blood pressure drops below 100 mmHg or orthostatic symptoms persist beyond 24 hours after dose reduction, discontinue VIP and reassess baseline cardiovascular status before restarting at 50 mcg per dose. We've worked with research teams who've successfully reintroduced VIP at lower doses after a 72-hour washout period, but cardiovascular monitoring must be consistent throughout re-titration.

Administer the missed dose as soon as you remember, provided fewer than 4 hours have passed since the scheduled time. VIP's short half-life means delayed doses still provide partial therapeutic coverage. If more than 4 hours have passed, skip the missed dose entirely and resume the regular schedule at the next interval. Do not double-dose to compensate. Receptor saturation from a single large dose creates more risk than benefit. Missing doses during titration may slow receptor adaptation slightly but does not reset the protocol unless multiple consecutive days are missed.

VIP accelerates gastrointestinal motility through direct effects on colonic smooth muscle and secretion. This is a known mechanism, not contamination. Reduce the dose by 25–50% and hold at that level for 10–14 days to allow the GI tract to adapt. If symptoms persist at the reduced dose, discontinue VIP and consider whether baseline gut motility was already elevated (IBS-D, post-infectious gut dysfunction). Most research protocols find that GI side effects resolve within two weeks of stable dosing, but forcing escalation through persistent diarrhoea compounds dehydration risk and undermines compliance.

Dose ipamorelin 2–3 times daily with at least 4–6 hours between administrations to preserve pulsatile signaling and avoid receptor desensitization. Continuous or overlapping dosing (e.g., every 2 hours) blunts the GH response by 30–40% within 7–10 days due to GHS-R1a receptor downregulation—a protective mechanism against sustained ghrelin signaling. The 2009 Growth Hormone & IGF Research study used three-times-daily dosing (morning, afternoon, evening) spaced 5–6 hours apart and maintained full GH pulse amplitude throughout 8 weeks. Spacing allows receptors to recycle and resensitize between pulses, preserving the physiologic pattern that optimizes downstream IGF-1 production.

Ipamorelin selective GH secretion produces minimal appetite stimulation compared to GHRP-6 or ghrelin itself, but approximately 15–20% of users report mild hunger increase 30–60 minutes post-injection. This is a partial ghrelin mimetic effect—GHS-R1a receptors exist in the hypothalamic arcuate nucleus (appetite regulation center), and ipamorelin's binding there can stimulate neuropeptide Y (NPY) and agouti-related peptide (AgRP), both orexigenic (appetite-stimulating) signals. The effect is dose-dependent and transient, lasting 1–2 hours. If appetite stimulation is undesirable, dose ipamorelin immediately after a meal when satiety signals (CCK, PYY, leptin) are elevated—this blunts the orexigenic response without affecting GH release.

Refrigerate reconstituted ipamorelin at 2–8°C immediately after mixing with bacteriostatic water—room temperature storage (20–25°C) causes approximately 15–20% potency loss within 48 hours and 40–50% loss within one week due to peptide bond hydrolysis. Lyophilized (freeze-dried) ipamorelin powder is stable at −20°C for 24–36 months, but once reconstituted, the aqueous environment accelerates degradation. A 2012 stability study in the Journal of Pharmaceutical Sciences measured ipamorelin degradation kinetics: samples stored at 25°C retained 82% potency at 48 hours and 58% at 7 days, while samples stored at 4°C retained 97% potency at 7 days and 89% at 28 days. Store reconstituted peptides in the refrigerator, not the freezer—freezing causes ice crystal formation that denatures protein structure.

Don't combine ipamorelin selective GH secretion with exogenous recombinant GH—there's no synergy, only redundancy and negative feedback. Exogenous GH suppresses endogenous GH secretion through negative feedback on the hypothalamic-pituitary axis (elevated IGF-1 inhibits GHRH and stimulates somatostatin release). If you administer recombinant GH, your pituitary stops making its own GH, rendering ipamorelin ineffective—it's stimulating a gland that's already shut down. A 2005 study in Hormone Research tested this exact scenario: subjects on recombinant GH replacement showed zero GH pulse response to GHRP-6 administration until 48–72 hours after stopping exogenous GH. Use one or the other, not both simultaneously.